COMPANY PROFILE

Amyloid Solution

Explore full profile

Innovative treatments targeting Alzheimer's disease through diverse pathological solutions

Seongnam-si, South KoreaFounded 2017Biotech & Life Sciences

Valuation $250–500M Last recorded · 2022

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Amyloid Solution

Amyloid Solution is a biotechnology company focused on developing innovative treatments for Alzheimer's disease. The company operates in the healthcare and pharmaceutical market, targeting patients at various stages of Alzheimer's with diverse pathological alterations. Amyloid Solution's business model revolves around research and development (R&D) of disease-modifying therapies, leveraging both domestic and international collaborations with key scientists and biopharma industries. The company generates revenue through investment rounds and partnerships, having raised significant funds from programs like TIPS and investors such as POSCO CAPITAL and KB Investment. Amyloid Solution also acquired Deargen, an AI-based drug development company, to enhance its R&D capabilities. The company aims to provide effective, safe, and diverse therapeutic solutions to combat Alzheimer's disease.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Seongnam-si, South Korea
Employees: 18
Open positions: None listed
Dealroom signal: 68.7/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2b
Investment activity: 1 company, latest Nov 2020
Capital deployed: $2.5M
Preferred round: SEED
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

6 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES COther financing	May 2022	$61M	$246M	Meta Investment · Industrial Bank of Korea · SK Securities	—
SERIES BOther financing	Apr 2020	$15M	$60M	Korea Development Bank	—

Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Amyloid Solution website traffic

Latest recorded traffic for Amyloid Solution is 1.7K monthly website visits, up 304.8% over the last three months. Amyloid Solution's team declined 5.3% over the past year.

Latest monthly visits1.7K 3-month web change+304.8% 1-year team growth-5.3%

Monthly website visitsOct 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATALTx TherapeuticsFirst-in-class precision oncology targeting immortal cancer cell pathways.	Houghton and Wyton, United Kingdom	Operational	—	$13M	$50M
TBTippingPoint BiosciencesTherapeutics company focused on drug discovery targeting the aberrant DNA in cancer cells	San Francisco, United States	Operational
KTKelonia TherapeuticsDeveloping a new wave of genetic medicines using its next generation vivo gene delivery platform	Boston, United States	Acquired
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational
ELEpigene LabsHelping cancer researchers develop new treatments and drugs by providing them with data-driven insights	Paris, France	Operational
RTRepare TherapeuticsDevelops precision cancer therapies using synthetic lethality and CRISPR-based discovery platforms	Montreal, Canada	Acquired
STSeekyo TherapeuticsA privately-owned biotech company developing a Smart Chemotherapy, selective to tumours, safe for patients	Saint-Maur-des-Fossés, France	Operational
SASapVaxDeveloping a suite of first-in-class cancer vaccines based on a novel self-adjuvanting peptide platform technology	Cleveland, United States	Operational